Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor’s Portfolio of next-gen CDK inhibitors for Treating Breast Cancer October 2, 2024
Enrollment completed in Ph 2 proof of concept 065-101 study of fadraciclib in patients with advanced solid tumors and lymphoma; ongoing in T-Cell Lymphoma cohort October 2, 2024
CARVYKTI significantly extends OS vs standard therapies for patients with multiple myeloma as early as second line October 2, 2024
Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or GEJ Cancer Expressing Claudin 18.2 October 2, 2024
EC approved toripalimab (LOQTORZI®) for the treatment of certain patients with mNPC and ESCC October 2, 2024
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362 October 2, 2024
Enrollment discontinued in Ph 3 KarMMa-9 study of Abecma with lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients with suboptimal response after autoSCT October 2, 2024
BLA submitted for accelerated approval for Telisotuzumab Vedotin (Teliso-V) in Previously Treated NSCLC with c-Met protein overexpression based on Ph 2 LUMINOSITY trial (M14-239) data October 2, 2024
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer October 2, 2024
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy October 2, 2024
Prime Medicine and BMS to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies October 2, 2024
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer October 2, 2024
